Shandong Huaan Biotechnology

Shandong Huaan Biotechnology specializes in the research, development, production, and sales of minimally invasive medical devices—most notably as an early innovator in biodegradable coronary heart stents in China. Their flagship product "Xinsorb" bioabsorbable rapamycin-eluting coronary stent has undergone extensive preclinical and clinical evaluation including animal studies and multiple phases of human trials. The company has received strong support from national science programs and regulatory agencies. Clinical milestones include completion of single-group enrollment studies, long-term animal experiments, randomized controlled trials, FIM study enrollment, and approval/listing of their Xinsorb bioabsorbable stent system.